Part Two Thinking About Antibody Validation
•Download as PPTX, PDF•
0 likes•683 views
Addressing the growing concerns associated with the use of commercial antibodies in research and in diagnostics.
Report
Share
Report
Share
Recommended
Part one thinking about antibody validation
This document discusses the need for standardized antibody validation in the antibody-based assay market. Currently, there is no oversight of what can be sold, leading to poor validation standards, unreliable results, wasted time and money, and reproducibility problems. It recommends increased scrutiny and validation of commercial antibodies to improve standards and ensure accurate, reproducible results.
Presentation of Andrew Chalmers in 1st International Antibody Validation For...
Presentation of Andrew Chalmers in 1st International Antibody Validation For...St John's Laboratory Ltd
Dr Chalmers is a cell biologist based at the University of Bath, UK and he currently leads a team investigating the role of stem cell regulators in prostate cancer. In 2014 he was promoted to a Senior Lectureship. Dr Chalmers have published over 25 peer reviewed papers, been invited to national and international conferences and been awarded major research grants from research councils and charities. He is also the founder of CiteAb, a citation based antibody search engine. The idea of CiteAb was birthed through frustration with using failed commercial antibodies. CiteAb aims to provide a better way for researchers to find antibodies which are suitable for their experiments. CiteAb was spun out of the University of Bath in January 2014 and Dr Chalmers is the currently the Chief Scientific Officer.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogRcpp11 useR2014
Rcpp11 is a header-only C++ library that targets C++11. It has a smaller code base than Rcpp and allows for faster compilation times due to reduced complexity. Rcpp11 introduces C++11 features like uniform initialization for creating NumericVectors and lambda functions that can be used with sapply. It is available on CRAN but evolves quickly, so the latest version should be installed from GitHub. The attributes package on GitHub contains functions for exporting C++ functions to R using attributes.
Antibodies for Immunohistochemistry (IHC)
Antibodies are compelling proteins that are essential to the immune system and extremely powerful in biotechnology applications; existing as major players in our defence against external agents (viruses, bacteria, etc.), they are also widely used as tools for research, diagnosis and treatments.
2014 11-27 EATRIS biomarkers platform, Amsterdam, oncology case study
Discussion of a case study of clinical biomarker validation, which was well executed but could not reproduce literature findings.
Innovative Coagulation Testing Technologies and Emerging Markets
This 650-page report provides an in-depth analysis of the coagulation testing market in 7 countries over the next decade. It explores technological trends, estimates market sizes and growth, profiles major players, and identifies opportunities for suppliers in centralized and decentralized testing. The growing cost pressures and technological advances will radically change coagulation testing practice, creating opportunities for new markers, quality controls, and products to facilitate testing closer to patients.
GeneMedi-Lateral Flow Immunoassay
Lateral flow immunoassay (LFIA) is a membrane-based technique that provides rapid, inexpensive, and easy-to-use detection of analytes in complex samples. Key advantages are low cost, ease of use without specialized equipment, and ability to provide results in minutes. LFIAs detect analytes using various formats, including sandwich assays that detect large analytes using two antibodies, and competitive assays that detect small analytes. LFIAs have applications in healthcare, agriculture, food/water quality testing, and more.
Pyrogrn Testing & MLT in pharmaceutical products.pptx
The document discusses pyrogen testing and microbial limit testing in pharmaceutical products. Pyrogen testing involves in vivo and in vitro methods to detect fever-causing substances such as bacterial endotoxins, which if present could cause adverse reactions. The rabbit pyrogen test was traditionally used but has mostly been replaced by the Limulus amebocyte lysate test and monocyte activation test due to limitations. Microbial limit testing determines the types and amounts of microorganisms present in non-sterile products to ensure they meet acceptable safety standards.
Recommended
Part one thinking about antibody validation
This document discusses the need for standardized antibody validation in the antibody-based assay market. Currently, there is no oversight of what can be sold, leading to poor validation standards, unreliable results, wasted time and money, and reproducibility problems. It recommends increased scrutiny and validation of commercial antibodies to improve standards and ensure accurate, reproducible results.
Presentation of Andrew Chalmers in 1st International Antibody Validation For...
Presentation of Andrew Chalmers in 1st International Antibody Validation For...St John's Laboratory Ltd
Dr Chalmers is a cell biologist based at the University of Bath, UK and he currently leads a team investigating the role of stem cell regulators in prostate cancer. In 2014 he was promoted to a Senior Lectureship. Dr Chalmers have published over 25 peer reviewed papers, been invited to national and international conferences and been awarded major research grants from research councils and charities. He is also the founder of CiteAb, a citation based antibody search engine. The idea of CiteAb was birthed through frustration with using failed commercial antibodies. CiteAb aims to provide a better way for researchers to find antibodies which are suitable for their experiments. CiteAb was spun out of the University of Bath in January 2014 and Dr Chalmers is the currently the Chief Scientific Officer.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogRcpp11 useR2014
Rcpp11 is a header-only C++ library that targets C++11. It has a smaller code base than Rcpp and allows for faster compilation times due to reduced complexity. Rcpp11 introduces C++11 features like uniform initialization for creating NumericVectors and lambda functions that can be used with sapply. It is available on CRAN but evolves quickly, so the latest version should be installed from GitHub. The attributes package on GitHub contains functions for exporting C++ functions to R using attributes.
Antibodies for Immunohistochemistry (IHC)
Antibodies are compelling proteins that are essential to the immune system and extremely powerful in biotechnology applications; existing as major players in our defence against external agents (viruses, bacteria, etc.), they are also widely used as tools for research, diagnosis and treatments.
2014 11-27 EATRIS biomarkers platform, Amsterdam, oncology case study
Discussion of a case study of clinical biomarker validation, which was well executed but could not reproduce literature findings.
Innovative Coagulation Testing Technologies and Emerging Markets
This 650-page report provides an in-depth analysis of the coagulation testing market in 7 countries over the next decade. It explores technological trends, estimates market sizes and growth, profiles major players, and identifies opportunities for suppliers in centralized and decentralized testing. The growing cost pressures and technological advances will radically change coagulation testing practice, creating opportunities for new markers, quality controls, and products to facilitate testing closer to patients.
GeneMedi-Lateral Flow Immunoassay
Lateral flow immunoassay (LFIA) is a membrane-based technique that provides rapid, inexpensive, and easy-to-use detection of analytes in complex samples. Key advantages are low cost, ease of use without specialized equipment, and ability to provide results in minutes. LFIAs detect analytes using various formats, including sandwich assays that detect large analytes using two antibodies, and competitive assays that detect small analytes. LFIAs have applications in healthcare, agriculture, food/water quality testing, and more.
Pyrogrn Testing & MLT in pharmaceutical products.pptx
The document discusses pyrogen testing and microbial limit testing in pharmaceutical products. Pyrogen testing involves in vivo and in vitro methods to detect fever-causing substances such as bacterial endotoxins, which if present could cause adverse reactions. The rabbit pyrogen test was traditionally used but has mostly been replaced by the Limulus amebocyte lysate test and monocyte activation test due to limitations. Microbial limit testing determines the types and amounts of microorganisms present in non-sterile products to ensure they meet acceptable safety standards.
Personalized Medicine: Genetic Diagnostics Technologies
As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing.
Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto
Setting up for successful lot release testing by Edmund Ang
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Setting up for successful lot release testing by Edmund Ang
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
View our webinar here: https://bit.ly/2lKNdWX
Many different impurities are present in or generated during biotherapy manufacturing. This webinar will address how process contaminates can arise from raw input materials, occur as residual processing agents, or form as reaction by-products. We will review strategies within product characterization to de-risk the manufacturing process, including the use of routine and high complexity assays; and the recommended testing to meet regulatory requirements for clinical submission. Learn methods to avoid costly pitfalls and implement procedures to expedite product quality decisions at critical junctures in your development plan. We will discuss two types of therapies:
Cell & Gene Therapies
Polyethylenimine (PEI) is a transfection agent used in nearly all cell and gene therapy products. We will review the regulations and the liquid chromatography with charged aerosol detection (LC-CAD) methodology to demonstrate PEI removal during the production process.
Monoclonal Antibodies (mAb) and Cell & Gene Therapies
During mAb manufacturing and inherent to Cell & Gene Therapies, a significant proportion of process impurities arise from the host cell used to express the drug. Host cell protein (HCP) impurities, present at PPM-levels, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. We will review why their complex and diverse nature makes them challenging to monitor, and theho best practices, specifically HCP identification by mass spectrometry, for detection.
Learning points:
1. Accurate detection and characterization of residual PEI in cell and gene therapy products
2. Effective detection and characterization of residual host cell proteins (HCP) in mAbs
3. Available technology and assays for quantifying process impurities
4. Current regulatory requirements for detecting, quantifying, and removing process impurities during biotherapy manufacturing
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
View our webinar here: https://bit.ly/2lKNdWX
Many different impurities are present in or generated during biotherapy manufacturing. This webinar will address how process contaminates can arise from raw input materials, occur as residual processing agents, or form as reaction by-products. We will review strategies within product characterization to de-risk the manufacturing process, including the use of routine and high complexity assays; and the recommended testing to meet regulatory requirements for clinical submission. Learn methods to avoid costly pitfalls and implement procedures to expedite product quality decisions at critical junctures in your development plan. We will discuss two types of therapies:
Cell & Gene Therapies
Polyethylenimine (PEI) is a transfection agent used in nearly all cell and gene therapy products. We will review the regulations and the liquid chromatography with charged aerosol detection (LC-CAD) methodology to demonstrate PEI removal during the production process.
Monoclonal Antibodies (mAb) and Cell & Gene Therapies
During mAb manufacturing and inherent to Cell & Gene Therapies, a significant proportion of process impurities arise from the host cell used to express the drug. Host cell protein (HCP) impurities, present at PPM-levels, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. We will review why their complex and diverse nature makes them challenging to monitor, and theho best practices, specifically HCP identification by mass spectrometry, for detection.
Learning points:
1. Accurate detection and characterization of residual PEI in cell and gene therapy products
2. Effective detection and characterization of residual host cell proteins (HCP) in mAbs
3. Available technology and assays for quantifying process impurities
4. Current regulatory requirements for detecting, quantifying, and removing process impurities during biotherapy manufacturing
Mouse & Rat Monoclonal Antibody
Mouse and Rat Monoclonal Antibody Development and Production. Hybridoma & Phage Display Technologies
Contact our technical team: info@biotem.fr
Visit our website: https://www.biotem-antibody.com/
Antibody validation
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
Low cost nutraceutical hypothesis testing
InVivo Biosystems provides concise in vivo testing of nutraceuticals using small animal models like C. elegans and zebrafish. They aim to help nutraceutical companies rapidly obtain efficacy and safety data to inform early decisions. Their process involves understanding a company's goals, designing customized experiments, and providing a complete data package within 3 months. A case study showed how their longevity testing helped a client obtain patent-worthy data to advance compound development within a tight timeline. InVivo Biosystems offers a cost-effective alternative to mammalian models for nutraceutical hypothesis testing and early proof-of-concept studies.
CRO Company for Mode of Action & Efficacy Test for Drugs | InvivoBiosystems
Compound testing takes shares of a huge part of the drug development and health-related compound market. In order to find a CRO that is both friendly for budget saving and efficient at the same time is not easy. IVB uses a three staged compound assessment which includes RNAseq, whole transcriptome analysis, and other techniques to help our clients better understand the mode of action and efficacy of a particular compound.
Immune Monitoring
The document discusses immune monitoring in vaccine trials. It provides context on regulatory requirements and the need for standardization. A variety of assays are used to assess cellular and antibody responses, including ELISPOT, flow cytometry, and neutralizing antibody assays [PRIMARY]. Challenges include the need for improved assays to measure antiviral function and mucosal responses. New technologies like single cell analysis and viral inhibition assays provide more detailed immune profiling but require significant bioinformatics support [SECONDARY]. The goal is to define immune correlates of protection to guide vaccine design, but this remains difficult without human challenge models [THIRDARY].
Best compound characterization protocol
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Finding Optimal Compound Dosage for Anti-Aging Drugs
Anti-aging compound becomes a very integral part of the compound market. However, the lack of experience in this field makes it very hard for testing CROs to fully understand the mechanism of actions as well as efficacy of the compound, particularly the optimal dosage for anti-aging use. In the following slide we are trying to share with you the best way to do testing on the substances that are designed for anti-aging use.
2013 US Hospital Coagulation Testing Market
This 411-page report from January 2013 analyzes the US hospital coagulation testing market. It provides volume and sales forecasts for 40 coagulation procedures performed in US hospitals through 2018. It reviews current instrumentation technologies and compares leading analyzers. It also profiles major suppliers of reagents and instruments, and identifies business opportunities in the market. The report is available for $6,300 for a single-user license and its table of contents covers topics like coagulation tests, instrumentation, technologies, the US market structure and size, and competitive assessments of major companies.
Good Model Organism for Anti Aging Testing
Drug testing is taking more attention than ever before in a fast growing market for longevity compounds. In order to succeed in a competitive market and develop a pipeline method for quick drug development, we need to understand and choose the most suitable model organism for aging studies. The following content is intended to provide information on how to choose the best model for anti-aging drug testing.
CON4EI-general-vs2
This document describes a project to develop a tiered testing strategy for assessing eye irritation using in vitro test methods. The project will evaluate 8 test methods using a set of 80 chemicals representing important drivers of eye irritation classification. The goal is to identify methods that can distinguish Category 1 chemicals from non-classified chemicals as well as Category 1 from Category 2 chemicals. The results will help define applicability domains and strengths/limitations of each method to establish a reliable tiered testing approach for eye irritation hazard identification and safety assessment.
PEGS Europe Protein & Antibody Engineering Summit 2014 Agenda
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Special Investigations
Special Investigations With;
Complement Fixation Test
Haemagglutination Inhibition Test
PCR – Polymerase Chain Reaction
Western Blot
Coomb’s Test
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
This document discusses strategies for preventing and detecting viral contamination in biologic manufacturing processes. It outlines sources of viral contamination including raw materials, facilities, and personnel. A multi-tiered approach is recommended involving screening raw materials and cell banks, in-process testing, and confirming downstream processes can clear viruses. Detection methods like in vitro and in vivo assays have limitations and next generation sequencing is presented as a powerful new tool to detect unknown viruses. Upstream prevention focuses on raw material control through pretreatment or virus-resistant cell lines while downstream processes aim to clear any contamination through viral inactivation or filtration steps. A holistic biosafety strategy applying prevention, detection, and removal approaches at all stages is emphasized.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
Alternative animal model for compound characterization
To pick a model is not easy thing to do, especially when nutraceutical market needs have to be met. Such market requires low budget, fast turn-around rate, and high-quality data at the same time. Traditional models such as mice and cell cultures usually only meet one need at one time. IVB uses C.elegans and zebrafish which lies in the middle of the model spectrum in terms of the three needs to perfectly accommodate all of them at the same time.
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia.
Anti-Smo antibody (STJ95710): http://www.stjohnslabs.com/smo-antibody-p-94371?filter_name=STJ95710
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)St John's Laboratory Ltd
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling . Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity). Has transcriptional activation and repression activity . Mediates glucocorticoid-induced apoptosis . Promotes accurate chromosome segregation during mitosis . May act as a tumor suppressor . May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity). / Isoform Beta: Acts as a dominant negative inhibitor of isoform Alpha . Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed.
Join our Antibody Validation Project: http://www.stjohnslabs.com/services/antibody-validation
Anti glucocorticoid receptor antibody (STJ97101):
http://www.stjohnslabs.com/glucocorticoid-receptor-antibody-p-98736?filter_name=STJ97101More Related Content
Similar to Part Two Thinking About Antibody Validation
Personalized Medicine: Genetic Diagnostics Technologies
As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing.
Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto
Setting up for successful lot release testing by Edmund Ang
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Setting up for successful lot release testing by Edmund Ang
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
View our webinar here: https://bit.ly/2lKNdWX
Many different impurities are present in or generated during biotherapy manufacturing. This webinar will address how process contaminates can arise from raw input materials, occur as residual processing agents, or form as reaction by-products. We will review strategies within product characterization to de-risk the manufacturing process, including the use of routine and high complexity assays; and the recommended testing to meet regulatory requirements for clinical submission. Learn methods to avoid costly pitfalls and implement procedures to expedite product quality decisions at critical junctures in your development plan. We will discuss two types of therapies:
Cell & Gene Therapies
Polyethylenimine (PEI) is a transfection agent used in nearly all cell and gene therapy products. We will review the regulations and the liquid chromatography with charged aerosol detection (LC-CAD) methodology to demonstrate PEI removal during the production process.
Monoclonal Antibodies (mAb) and Cell & Gene Therapies
During mAb manufacturing and inherent to Cell & Gene Therapies, a significant proportion of process impurities arise from the host cell used to express the drug. Host cell protein (HCP) impurities, present at PPM-levels, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. We will review why their complex and diverse nature makes them challenging to monitor, and theho best practices, specifically HCP identification by mass spectrometry, for detection.
Learning points:
1. Accurate detection and characterization of residual PEI in cell and gene therapy products
2. Effective detection and characterization of residual host cell proteins (HCP) in mAbs
3. Available technology and assays for quantifying process impurities
4. Current regulatory requirements for detecting, quantifying, and removing process impurities during biotherapy manufacturing
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
View our webinar here: https://bit.ly/2lKNdWX
Many different impurities are present in or generated during biotherapy manufacturing. This webinar will address how process contaminates can arise from raw input materials, occur as residual processing agents, or form as reaction by-products. We will review strategies within product characterization to de-risk the manufacturing process, including the use of routine and high complexity assays; and the recommended testing to meet regulatory requirements for clinical submission. Learn methods to avoid costly pitfalls and implement procedures to expedite product quality decisions at critical junctures in your development plan. We will discuss two types of therapies:
Cell & Gene Therapies
Polyethylenimine (PEI) is a transfection agent used in nearly all cell and gene therapy products. We will review the regulations and the liquid chromatography with charged aerosol detection (LC-CAD) methodology to demonstrate PEI removal during the production process.
Monoclonal Antibodies (mAb) and Cell & Gene Therapies
During mAb manufacturing and inherent to Cell & Gene Therapies, a significant proportion of process impurities arise from the host cell used to express the drug. Host cell protein (HCP) impurities, present at PPM-levels, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. We will review why their complex and diverse nature makes them challenging to monitor, and theho best practices, specifically HCP identification by mass spectrometry, for detection.
Learning points:
1. Accurate detection and characterization of residual PEI in cell and gene therapy products
2. Effective detection and characterization of residual host cell proteins (HCP) in mAbs
3. Available technology and assays for quantifying process impurities
4. Current regulatory requirements for detecting, quantifying, and removing process impurities during biotherapy manufacturing
Mouse & Rat Monoclonal Antibody
Mouse and Rat Monoclonal Antibody Development and Production. Hybridoma & Phage Display Technologies
Contact our technical team: info@biotem.fr
Visit our website: https://www.biotem-antibody.com/
Antibody validation
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
Low cost nutraceutical hypothesis testing
InVivo Biosystems provides concise in vivo testing of nutraceuticals using small animal models like C. elegans and zebrafish. They aim to help nutraceutical companies rapidly obtain efficacy and safety data to inform early decisions. Their process involves understanding a company's goals, designing customized experiments, and providing a complete data package within 3 months. A case study showed how their longevity testing helped a client obtain patent-worthy data to advance compound development within a tight timeline. InVivo Biosystems offers a cost-effective alternative to mammalian models for nutraceutical hypothesis testing and early proof-of-concept studies.
CRO Company for Mode of Action & Efficacy Test for Drugs | InvivoBiosystems
Compound testing takes shares of a huge part of the drug development and health-related compound market. In order to find a CRO that is both friendly for budget saving and efficient at the same time is not easy. IVB uses a three staged compound assessment which includes RNAseq, whole transcriptome analysis, and other techniques to help our clients better understand the mode of action and efficacy of a particular compound.
Immune Monitoring
The document discusses immune monitoring in vaccine trials. It provides context on regulatory requirements and the need for standardization. A variety of assays are used to assess cellular and antibody responses, including ELISPOT, flow cytometry, and neutralizing antibody assays [PRIMARY]. Challenges include the need for improved assays to measure antiviral function and mucosal responses. New technologies like single cell analysis and viral inhibition assays provide more detailed immune profiling but require significant bioinformatics support [SECONDARY]. The goal is to define immune correlates of protection to guide vaccine design, but this remains difficult without human challenge models [THIRDARY].
Best compound characterization protocol
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Finding Optimal Compound Dosage for Anti-Aging Drugs
Anti-aging compound becomes a very integral part of the compound market. However, the lack of experience in this field makes it very hard for testing CROs to fully understand the mechanism of actions as well as efficacy of the compound, particularly the optimal dosage for anti-aging use. In the following slide we are trying to share with you the best way to do testing on the substances that are designed for anti-aging use.
2013 US Hospital Coagulation Testing Market
This 411-page report from January 2013 analyzes the US hospital coagulation testing market. It provides volume and sales forecasts for 40 coagulation procedures performed in US hospitals through 2018. It reviews current instrumentation technologies and compares leading analyzers. It also profiles major suppliers of reagents and instruments, and identifies business opportunities in the market. The report is available for $6,300 for a single-user license and its table of contents covers topics like coagulation tests, instrumentation, technologies, the US market structure and size, and competitive assessments of major companies.
Good Model Organism for Anti Aging Testing
Drug testing is taking more attention than ever before in a fast growing market for longevity compounds. In order to succeed in a competitive market and develop a pipeline method for quick drug development, we need to understand and choose the most suitable model organism for aging studies. The following content is intended to provide information on how to choose the best model for anti-aging drug testing.
CON4EI-general-vs2
This document describes a project to develop a tiered testing strategy for assessing eye irritation using in vitro test methods. The project will evaluate 8 test methods using a set of 80 chemicals representing important drivers of eye irritation classification. The goal is to identify methods that can distinguish Category 1 chemicals from non-classified chemicals as well as Category 1 from Category 2 chemicals. The results will help define applicability domains and strengths/limitations of each method to establish a reliable tiered testing approach for eye irritation hazard identification and safety assessment.
PEGS Europe Protein & Antibody Engineering Summit 2014 Agenda
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Special Investigations
Special Investigations With;
Complement Fixation Test
Haemagglutination Inhibition Test
PCR – Polymerase Chain Reaction
Western Blot
Coomb’s Test
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
This document discusses strategies for preventing and detecting viral contamination in biologic manufacturing processes. It outlines sources of viral contamination including raw materials, facilities, and personnel. A multi-tiered approach is recommended involving screening raw materials and cell banks, in-process testing, and confirming downstream processes can clear viruses. Detection methods like in vitro and in vivo assays have limitations and next generation sequencing is presented as a powerful new tool to detect unknown viruses. Upstream prevention focuses on raw material control through pretreatment or virus-resistant cell lines while downstream processes aim to clear any contamination through viral inactivation or filtration steps. A holistic biosafety strategy applying prevention, detection, and removal approaches at all stages is emphasized.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
Alternative animal model for compound characterization
To pick a model is not easy thing to do, especially when nutraceutical market needs have to be met. Such market requires low budget, fast turn-around rate, and high-quality data at the same time. Traditional models such as mice and cell cultures usually only meet one need at one time. IVB uses C.elegans and zebrafish which lies in the middle of the model spectrum in terms of the three needs to perfectly accommodate all of them at the same time.
Similar to Part Two Thinking About Antibody Validation (20)
Personalized Medicine: Genetic Diagnostics Technologies
Personalized Medicine: Genetic Diagnostics Technologies
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
CRO Company for Mode of Action & Efficacy Test for Drugs | InvivoBiosystems
CRO Company for Mode of Action & Efficacy Test for Drugs | InvivoBiosystems
Finding Optimal Compound Dosage for Anti-Aging Drugs
Finding Optimal Compound Dosage for Anti-Aging Drugs
PEGS Europe Protein & Antibody Engineering Summit 2014 Agenda
PEGS Europe Protein & Antibody Engineering Summit 2014 Agenda
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Alternative animal model for compound characterization
Alternative animal model for compound characterization
More from St John's Laboratory Ltd
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia.
Anti-Smo antibody (STJ95710): http://www.stjohnslabs.com/smo-antibody-p-94371?filter_name=STJ95710
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)St John's Laboratory Ltd
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling . Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity). Has transcriptional activation and repression activity . Mediates glucocorticoid-induced apoptosis . Promotes accurate chromosome segregation during mitosis . May act as a tumor suppressor . May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity). / Isoform Beta: Acts as a dominant negative inhibitor of isoform Alpha . Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed.
Join our Antibody Validation Project: http://www.stjohnslabs.com/services/antibody-validation
Anti glucocorticoid receptor antibody (STJ97101):
http://www.stjohnslabs.com/glucocorticoid-receptor-antibody-p-98736?filter_name=STJ97101Western Blot Customer Review Anti-Phospho-Cofilin (S3) Antibody (STJ90230)
Binds to F-actin and exhibits pH-sensitive F-actin depolymerizing activity. Regulates actin cytoskeleton dynamics. Important for normal progress through mitosis and normal cytokinesis. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required for the up-regulation of atypical chemokine receptor ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation.
Anti-Phospho-Cofilin (S3) -http://www.stjohnslabs.com/phospho-cofilin-s3-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Scientist of the Month - May Byron Baron
This June, Dr. Byron Baron from the University of Malta, Malta, is our Scientist of the Month! He's shared with us his research highlights, his current projects and some comments on the biotechnology industry.
Want to be our Scientist of the Month? Contact info@stjohnslabs.com
Western Blot Customer Review Anti-WAVE2 Antibody (STJ96263)
Downstream effector molecule involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Promotes formation of actin filaments. Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex.
Anti-WAVE2 -http://www.stjohnslabs.com/wave2-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti-Endophilin I Antibody (STJ92924)
Implicated in synaptic vesicle endocytosis. May recruit other proteins to membranes with high curvature.
Brain, mostly in frontal cortex. Expressed at high level in fetal cerebellum.
Anti-Endophilin I -http://www.stjohnslabs.com/endophilin-i-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti-β-tubulin Antibody (STJ97037)
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. TUBB3 plays a critical role in proper axon guidance and mantainance.
Anti-β-tubulin -http://www.stjohnslabs.com/b-tubulin-antibody-p-98672
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...St John's Laboratory Ltd
Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death. Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. / Strict requirement for Asp at position P1 and has a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). / Inhibited by the effector protein NleF that is produced by pathogenic E.coli; this inhibits apoptosis.
Anti-Caspase-8-http://www.stjohnslabs.com/caspase-8-antibody-p-99045
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...
Immunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...St John's Laboratory Ltd
Tubulin is the major constituent of microtubules. The gamma chain is found at microtubule organizing centers (MTOC) such as the spindle poles or the centrosome. Pericentriolar matrix component that regulates alpha/beta chain minus-end nucleation, centrosome duplication and spindle formation.
Anti-Gamma Tubulin-http://www.stjohnslabs.com/gamma-tubulin-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...St John's Laboratory Ltd
This document describes immunohistochemistry protocols for validating an anti-epsilon tubulin antibody in paraffin-embedded tissue samples of human liver, rat lung, kidney, spleen, and mouse lung. The protocol involves tissue processing, antigen retrieval, blocking, primary and secondary antibody incubation, DAB staining, hematoxylin counterstaining, dehydration, clearing, and visualization under a microscope. Validation results showed specific staining of epsilon tubulin in the tissue samples.Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...
Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...St John's Laboratory Ltd
Produces green light with a wavelength of 562 nm. / Photinus luciferin + O2 + ATP = oxidized Photinus luciferin + CO2 + AMP + diphosphate + light.
Anti-Luciferase -http://www.stjohnslabs.com/luciferase-antibody-2
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...St John's Laboratory Ltd
Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes) . Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation .
Anti-LC3A-http://www.stjohnslabs.com/lc3a-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...St John's Laboratory Ltd
Multifunctional transcription factor in ER stress response. Plays an essential role in the response to a wide variety of cell stresses and induces cell cycle arrest and apoptosis in response to ER stress. Plays a dual role both as an inhibitor of CCAAT/enhancer-binding protein (C/EBP) function and as an activator of other genes. Acts as a dominant-negative regulator of C/EBP-induced transcription: dimerizes with members of the C/EBP family, impairs their association with C/EBP binding sites in the promoter regions, and inhibits the expression of C/EBP regulated genes. Positively regulates the transcription of TRIB3, IL6, IL8, IL23, TNFRSF10B/DR5, PPP1R15A/GADD34, BBC3/PUMA, BCL2L11/BIM and ERO1L. Negatively regulates; expression of BCL2 and MYOD1, ATF4-dependent transcriptional activation of asparagine synthetase (ASNS), CEBPA-dependent transcriptional activation of hepcidin (HAMP) and CEBPB-mediated expression of peroxisome proliferator-activated receptor gamma (PPARG).
Anti-CHOP-http://www.stjohnslabs.com/chop-antibody-2
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...
Immunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...St John's Laboratory Ltd
Pseudokinase that plays a key role in TNF-induced necroptosis, a programmed cell death process. Activated following phosphorylation by RIPK3, leading to homotrimerization, localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage. Does not have protein kinase activity.
Anti-phospho-MLKL (S358)-http://www.stjohnslabs.com/phospho-mlkl-s358-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...St John's Laboratory Ltd
This document summarizes the immunohistochemistry protocol used to analyze ERK1 protein expression in human uterus tissue samples. Key steps included: antigen retrieval using citric acid; blocking of endogenous peroxidase; primary antibody incubation with anti-ERK1 antibody overnight at 4°C; secondary antibody incubation at room temperature for 30 minutes; DAB staining to visualize positive results; hematoxylin counterstaining; dehydration and clearing of slides; and visualization under a microscope. The protocol validated that the anti-ERK1 antibody specifically labeled ERK1 protein in human uterus tissue as expected.Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...
Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...St John's Laboratory Ltd
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation.
Anti-PDGFRα-http://www.stjohnslabs.com/pdgfra-antibody-2
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...St John's Laboratory Ltd
Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis. / Strict requirement for an Asp residue at position P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-. / Specifically inhibited by the cowpox virus Crma protein.
Anti-Caspase-1-http://www.stjohnslabs.com/caspase-1-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...St John's Laboratory Ltd
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu2+-mediated low-density lipoprotein oxidation.
Anti-Amyloid-β-http://www.stjohnslabs.com/amyloid-v-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...St John's Laboratory Ltd
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release .
Anti-Bcl-2-http://www.stjohnslabs.com/bcl-2-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...St John's Laboratory Ltd
Alpha-actin-2 also known as actin, aortic smooth muscle or alpha smooth muscle actin (α-SMA, SMactin, alpha-SM-actin, ASMA) is a protein that in humans is encoded by the ACTA2 gene located on 10q22-q24. Actin alpha 2, the human aortic smooth muscle actin gene, is one of six different actin isoforms which have been identified. Actins are highly conserved proteins that are involved in cell motility, structure and integrity. Alpha actins are a major constituent of the contractile apparatus. Alpha-smooth muscle actin (α-SMA) is commonly used as a marker of myofibroblast formation.
Anti-α-SMA -http://www.stjohnslabs.com/a-sma-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationMore from St John's Laboratory Ltd (20)
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti-Phospho-Cofilin (S3) Antibody (STJ90230)
Western Blot Customer Review Anti-Phospho-Cofilin (S3) Antibody (STJ90230)
Western Blot Customer Review Anti-WAVE2 Antibody (STJ96263)
Western Blot Customer Review Anti-WAVE2 Antibody (STJ96263)
Western Blot Customer Review Anti-Endophilin I Antibody (STJ92924)
Western Blot Customer Review Anti-Endophilin I Antibody (STJ92924)
Western Blot Customer Review Anti-β-tubulin Antibody (STJ97037)
Western Blot Customer Review Anti-β-tubulin Antibody (STJ97037)
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...
Immunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...
Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...
Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...
Immunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...
Immunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...
Immunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...
Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...
Recently uploaded
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
Context. The early-type galaxy SDSS J133519.91+072807.4 (hereafter SDSS1335+0728), which had exhibited no prior optical variations during the preceding two decades, began showing significant nuclear variability in the Zwicky Transient Facility (ZTF) alert stream from December 2019 (as ZTF19acnskyy). This variability behaviour, coupled with the host-galaxy properties, suggests that SDSS1335+0728 hosts a ∼ 106M⊙ black hole (BH) that is currently in the process of ‘turning on’. Aims. We present a multi-wavelength photometric analysis and spectroscopic follow-up performed with the aim of better understanding the origin of the nuclear variations detected in SDSS1335+0728. Methods. We used archival photometry (from WISE, 2MASS, SDSS, GALEX, eROSITA) and spectroscopic data (from SDSS and LAMOST) to study the state of SDSS1335+0728 prior to December 2019, and new observations from Swift, SOAR/Goodman, VLT/X-shooter, and Keck/LRIS taken after its turn-on to characterise its current state. We analysed the variability of SDSS1335+0728 in the X-ray/UV/optical/mid-infrared range, modelled its spectral energy distribution prior to and after December 2019, and studied the evolution of its UV/optical spectra. Results. From our multi-wavelength photometric analysis, we find that: (a) since 2021, the UV flux (from Swift/UVOT observations) is four times brighter than the flux reported by GALEX in 2004; (b) since June 2022, the mid-infrared flux has risen more than two times, and the W1−W2 WISE colour has become redder; and (c) since February 2024, the source has begun showing X-ray emission. From our spectroscopic follow-up, we see that (i) the narrow emission line ratios are now consistent with a more energetic ionising continuum; (ii) broad emission lines are not detected; and (iii) the [OIII] line increased its flux ∼ 3.6 years after the first ZTF alert, which implies a relatively compact narrow-line-emitting region. Conclusions. We conclude that the variations observed in SDSS1335+0728 could be either explained by a ∼ 106M⊙ AGN that is just turning on or by an exotic tidal disruption event (TDE). If the former is true, SDSS1335+0728 is one of the strongest cases of an AGNobserved in the process of activating. If the latter were found to be the case, it would correspond to the longest and faintest TDE ever observed (or another class of still unknown nuclear transient). Future observations of SDSS1335+0728 are crucial to further understand its behaviour. Key words. galaxies: active– accretion, accretion discs– galaxies: individual: SDSS J133519.91+072807.4
11.1 Role of physical biological in deterioration of grains.pdf
Storagedeteriorationisanyformoflossinquantityandqualityofbio-materials.
Themajorcausesofdeteriorationinstorage
•Physical
•Biological
•Mechanical
•Chemical
Storageonlypreservesquality.Itneverimprovesquality.
Itisadvisabletostartstoragewithqualityfoodproduct.Productwithinitialpoorqualityquicklydepreciates
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...ABHISHEK SONI NIMT INSTITUTE OF MEDICAL AND PARAMEDCIAL SCIENCES , GOVT PG COLLEGE NOIDA
Microbial interaction
Microorganisms interacts with each other and can be physically associated with another organisms in a variety of ways.
One organism can be located on the surface of another organism as an ectobiont or located within another organism as endobiont.
Microbial interaction may be positive such as mutualism, proto-cooperation, commensalism or may be negative such as parasitism, predation or competition
Types of microbial interaction
Positive interaction: mutualism, proto-cooperation, commensalism
Negative interaction: Ammensalism (antagonism), parasitism, predation, competition
I. Mutualism:
It is defined as the relationship in which each organism in interaction gets benefits from association. It is an obligatory relationship in which mutualist and host are metabolically dependent on each other.
Mutualistic relationship is very specific where one member of association cannot be replaced by another species.
Mutualism require close physical contact between interacting organisms.
Relationship of mutualism allows organisms to exist in habitat that could not occupied by either species alone.
Mutualistic relationship between organisms allows them to act as a single organism.
Examples of mutualism:
i. Lichens:
Lichens are excellent example of mutualism.
They are the association of specific fungi and certain genus of algae. In lichen, fungal partner is called mycobiont and algal partner is called
II. Syntrophism:
It is an association in which the growth of one organism either depends on or improved by the substrate provided by another organism.
In syntrophism both organism in association gets benefits.
Compound A
Utilized by population 1
Compound B
Utilized by population 2
Compound C
utilized by both Population 1+2
Products
In this theoretical example of syntrophism, population 1 is able to utilize and metabolize compound A, forming compound B but cannot metabolize beyond compound B without co-operation of population 2. Population 2is unable to utilize compound A but it can metabolize compound B forming compound C. Then both population 1 and 2 are able to carry out metabolic reaction which leads to formation of end product that neither population could produce alone.
Examples of syntrophism:
i. Methanogenic ecosystem in sludge digester
Methane produced by methanogenic bacteria depends upon interspecies hydrogen transfer by other fermentative bacteria.
Anaerobic fermentative bacteria generate CO2 and H2 utilizing carbohydrates which is then utilized by methanogenic bacteria (Methanobacter) to produce methane.
ii. Lactobacillus arobinosus and Enterococcus faecalis:
In the minimal media, Lactobacillus arobinosus and Enterococcus faecalis are able to grow together but not alone.
The synergistic relationship between E. faecalis and L. arobinosus occurs in which E. faecalis require folic acid
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Context. The observation of several L-band emission sources in the S cluster has led to a rich discussion of their nature. However, a definitive answer to the classification of the dusty objects requires an explanation for the detection of compact Doppler-shifted Brγ emission. The ionized hydrogen in combination with the observation of mid-infrared L-band continuum emission suggests that most of these sources are embedded in a dusty envelope. These embedded sources are part of the S-cluster, and their relationship to the S-stars is still under debate. To date, the question of the origin of these two populations has been vague, although all explanations favor migration processes for the individual cluster members. Aims. This work revisits the S-cluster and its dusty members orbiting the supermassive black hole SgrA* on bound Keplerian orbits from a kinematic perspective. The aim is to explore the Keplerian parameters for patterns that might imply a nonrandom distribution of the sample. Additionally, various analytical aspects are considered to address the nature of the dusty sources. Methods. Based on the photometric analysis, we estimated the individual H−K and K−L colors for the source sample and compared the results to known cluster members. The classification revealed a noticeable contrast between the S-stars and the dusty sources. To fit the flux-density distribution, we utilized the radiative transfer code HYPERION and implemented a young stellar object Class I model. We obtained the position angle from the Keplerian fit results; additionally, we analyzed the distribution of the inclinations and the longitudes of the ascending node. Results. The colors of the dusty sources suggest a stellar nature consistent with the spectral energy distribution in the near and midinfrared domains. Furthermore, the evaporation timescales of dusty and gaseous clumps in the vicinity of SgrA* are much shorter ( 2yr) than the epochs covered by the observations (≈15yr). In addition to the strong evidence for the stellar classification of the D-sources, we also find a clear disk-like pattern following the arrangements of S-stars proposed in the literature. Furthermore, we find a global intrinsic inclination for all dusty sources of 60 ± 20◦, implying a common formation process. Conclusions. The pattern of the dusty sources manifested in the distribution of the position angles, inclinations, and longitudes of the ascending node strongly suggests two different scenarios: the main-sequence stars and the dusty stellar S-cluster sources share a common formation history or migrated with a similar formation channel in the vicinity of SgrA*. Alternatively, the gravitational influence of SgrA* in combination with a massive perturber, such as a putative intermediate mass black hole in the IRS 13 cluster, forces the dusty objects and S-stars to follow a particular orbital arrangement. Key words. stars: black holes– stars: formation– Galaxy: center– galaxies: star formation
Mechanisms and Applications of Antiviral Neutralizing Antibodies - Creative B...
Neutralizing antibodies, pivotal in immune defense, specifically bind and inhibit viral pathogens, thereby playing a crucial role in protecting against and mitigating infectious diseases. In this slide, we will introduce what antibodies and neutralizing antibodies are, the production and regulation of neutralizing antibodies, their mechanisms of action, classification and applications, as well as the challenges they face.
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdf
Ozturkcan, S., Berndt, A., & Angelakis, A. (2024). Mending clothing to support sustainable fashion. Presented at the 31st Annual Conference by the Consortium for International Marketing Research (CIMaR), 10-13 Jun 2024, University of Gävle, Sweden.
Male reproduction physiology by Suyash Garg .pptx
Physiology of Male reproduction.
Video mentioned at page no. 23 as summary for better understanding
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
Centrifugation is a powerful technique used in laboratories to separate components of a heterogeneous mixture based on their density. This process utilizes centrifugal force to rapidly spin samples, causing denser particles to migrate outward more quickly than lighter ones. As a result, distinct layers form within the sample tube, allowing for easy isolation and purification of target substances.
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Wereport the study of a huge optical intraday flare on 2021 November 12 at 2 a.m. UT in the blazar OJ287. In the binary black hole model, it is associated with an impact of the secondary black hole on the accretion disk of the primary. Our multifrequency observing campaign was set up to search for such a signature of the impact based on a prediction made 8 yr earlier. The first I-band results of the flare have already been reported by Kishore et al. (2024). Here we combine these data with our monitoring in the R-band. There is a big change in the R–I spectral index by 1.0 ±0.1 between the normal background and the flare, suggesting a new component of radiation. The polarization variation during the rise of the flare suggests the same. The limits on the source size place it most reasonably in the jet of the secondary BH. We then ask why we have not seen this phenomenon before. We show that OJ287 was never before observed with sufficient sensitivity on the night when the flare should have happened according to the binary model. We also study the probability that this flare is just an oversized example of intraday variability using the Krakow data set of intense monitoring between 2015 and 2023. We find that the occurrence of a flare of this size and rapidity is unlikely. In machine-readable Tables 1 and 2, we give the full orbit-linked historical light curve of OJ287 as well as the dense monitoring sample of Krakow.
一比一原版美国佩斯大学毕业证如何办理
原版一模一样【微信：741003700 】【美国佩斯大学毕业证成绩单】【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
办理美国佩斯大学毕业证【微信：741003700 】外观非常简单，由纸质材料制成，上面印有校徽、校名、毕业生姓名、专业等信息。
办理美国佩斯大学毕业证【微信：741003700 】格式相对统一，各专业都有相应的模板。通常包括以下部分：
校徽：象征着学校的荣誉和传承。
校名:学校英文全称
授予学位：本部分将注明获得的具体学位名称。
毕业生姓名：这是最重要的信息之一，标志着该证书是由特定人员获得的。
颁发日期：这是毕业正式生效的时间，也代表着毕业生学业的结束。
其他信息：根据不同的专业和学位，可能会有一些特定的信息或章节。
办理美国佩斯大学毕业证【微信：741003700 】价值很高，需要妥善保管。一般来说，应放置在安全、干燥、防潮的地方，避免长时间暴露在阳光下。如需使用，最好使用复印件而不是原件，以免丢失。
综上所述，办理美国佩斯大学毕业证【微信：741003700 】是证明身份和学历的高价值文件。外观简单庄重，格式统一，包括重要的个人信息和发布日期。对持有人来说，妥善保管是非常重要的。
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
快速办理(UAM毕业证书)马德里自治大学毕业证学位证一模一样
学校原件一模一样【微信：741003700 】《(UAM毕业证书)马德里自治大学毕业证学位证》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Signatures of wave erosion in Titan’s coasts
The shorelines of Titan’s hydrocarbon seas trace flooded erosional landforms such as river valleys; however, it isunclear whether coastal erosion has subsequently altered these shorelines. Spacecraft observations and theo-retical models suggest that wind may cause waves to form on Titan’s seas, potentially driving coastal erosion,but the observational evidence of waves is indirect, and the processes affecting shoreline evolution on Titanremain unknown. No widely accepted framework exists for using shoreline morphology to quantitatively dis-cern coastal erosion mechanisms, even on Earth, where the dominant mechanisms are known. We combinelandscape evolution models with measurements of shoreline shape on Earth to characterize how differentcoastal erosion mechanisms affect shoreline morphology. Applying this framework to Titan, we find that theshorelines of Titan’s seas are most consistent with flooded landscapes that subsequently have been eroded bywaves, rather than a uniform erosional process or no coastal erosion, particularly if wave growth saturates atfetch lengths of tens of kilometers.
Recently uploaded (20)
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
Nutaceuticsls herbal drug technology CVS, cancer.pptx
Nutaceuticsls herbal drug technology CVS, cancer.pptx
11.1 Role of physical biological in deterioration of grains.pdf
11.1 Role of physical biological in deterioration of grains.pdf
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Juaristi, Jon. - El canon espanol. El legado de la cultura española a la civi...
Juaristi, Jon. - El canon espanol. El legado de la cultura española a la civi...
Mechanisms and Applications of Antiviral Neutralizing Antibodies - Creative B...
Mechanisms and Applications of Antiviral Neutralizing Antibodies - Creative B...
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdf
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdf
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
Part Two Thinking About Antibody Validation
- 2. Who is addressing this problem?
- 4. What recommendations have been made?
- 5. Summary Bordeaux et al 2010 • No universal standard for antibodies • Highlighting common pitfalls in commercial antibodies • Lack of studies of antibody reproducibility • Rimm Lab Algorithm established to address the gap for antibody validation standardization • Algorithm is for IHC or QIF on paraffin-embedded tissues • 5 stages/levels to reach conclusion (see figure 3)
- 6. Figure 3. The Rimm Lab Algorithm for antibody validation of IHC/QIF The Rimm Lab Algorithm for antibody validation of IHC/QIF Step 1 of antibody validation is using cell lines in vitro to test antibody specificity. Step 2 (below the dotted line) involves further validation of antibody on tissue microarray (TMA) for expected target localization and reproducibility between assay runs and different antibody lots.
- 8. Join Us! At The International Antibody Validation Forum October 15th 2014 10:30am – 4:00pm Free Admission The Octagon, Queen Mary University of London Mile End Road, E1 4NS, UK Registration Enquires: info@stjohnslabs.com
- 9. Are there any other contributors to this growing issue?
- 10. Yes! Find out in Part 3
- 11. 1. Bordeaux J, Welsh A, Agarwal S, Killiam E, BaqueroM, Hanna J, Anagnostou V, Rimm D. Antibody validation. Biotechniques. 2010 Mar;48(3):197-209. 1. Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012 Jan 1;18(1):118-26.